-
-
-
-
-
-
-
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens Ahead of Phase 1/2 BIRD-1 Trial
-
-
-
-
-
-
-
RBC Capital Starts Opus Genetics (IRD) at Outperform
-
-
-
-
-
-
-
Opus Genetics (IRD) PT Lowered to $11 at Citizens on More Dilutive Shares in 10-Q
-
-
-
-
-
-
-
Cantor Fitzgerald Starts Opus Genetics (IRD) at Overweight
-
-
-
-
-
-
-
Opus Genetics begins gene therapy trial for rare eye disease
-
-
-
-
-
-
-
Wedbush Starts Opus Genetics (IRD) at Outperform
-
-
-
-
-
-
-
Opus Genetics (IRD) CFO departs; Amy Rabourn named interim principal financial officer
-
460,595 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

